Journal of Medical Economics

Article	Citations
Health outcomes and economic burden of hospitalized COVID-19 patients in the United States	129
The Global South political economy of health financing and spending landscape – history and presence	72
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis	44
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2	39
Iran, sanctions, and the COVID-19 crisis	38
Asian innovation in pharmaceutical and medical device industry – beyond tomorrow	33
How China controls the Covid-19 epidemic through public health expenditure and policy?	32
Cost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom	25
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison	24
Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment	23
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United Sta	23
Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States	23
Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs	22
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer	22
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China	20
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective	20
The societal economic value of COVID-19 vaccines in the United States	19
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome	19
Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endom	18
Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder	18
Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?	16
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim	16
Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019	16
Mean lifetime survival estimates following solid organ transplantation in the US and UK	15
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States	15

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegf	15
Composite outcome measurement in clinical research: the triumph of illusion over reality?	15
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer	14
Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)	14
The six Delta platform for outcome-based contracting for pharmaceuticals	14
Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee	14
Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model	13
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology	13
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom	13
Consequences of India’s population aging to its healthcare financing and provision	13
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers	12
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers	12
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States	12
Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany	12
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective	12
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States	12
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States	12
Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK	12
Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific	12
Impact of an active hemostatic product treatment approach on bleeding-related complications and hospital costs among inpatient surgeries in the United States	11
Carbon footprint and associated costs of asthma exacerbation care among UK adults	11
Burden of caring for Alzheimer’s disease or dementia patients in Japan, the US, and EU: results from the National Health and Wellness Survey: a cross-sectional survey	11
Assessing the burden of nocturia in the workplace: the associations between nocturnal voiding, subjective well-being, work engagement and productivity	11
The direct and indirect economic burden of hypothyroidism in the United States: a retrospective claims database study	11
Applications of AI in pharmacy practice: a look at hospital and community settings	11
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States	11
Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria	11
Humanistic burden among caregivers of patients with Alzheimer’s disease or dementia in Japan: a large-scale cross-sectional survey	11
Healthcare resource use and indirect costs associated with migraine in Italy: results from theMy Migraine Voicesurvey	11
An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK	10
Technical and regulatory challenges of digital health implementation in developing countries	10
Cost utility analysis of continuous and intermittent versus intermittent vital signs monitoring in patients admitted to surgical wards	10
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	10
The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries	10
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model	10
Rational drug use in hospital settings – areas that can be changed	10
Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease	10
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data:	10
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	10
Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong	10
Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries	10
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK	10
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23	10
Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011–2017)	10
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	10
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	10
Modeling the economic value of Ceribell Rapid Response EEG in the inpatient hospital setting	10
Modelling the value of innovative treatments for Alzheimer’s disease in the United States	9
Productivity loss and productivity loss costs to United States employers due to priority conditions: a systematic review	9
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan	9

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer	9
Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States	9
Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain	9
Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States	9
Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China	9
The impact of transparency constraints on the efficiency of the Russian healthcare system: systematic literature review	9
COVID-19-associated hospitalizations among children less than 12 years of age in the United States	9
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer	9
Economic burden for retinoblastoma patients in China	9
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States	9
The impact of frailty on the economic evaluation of geriatric surgery: hospital costs and opportunity costs based on meta-analysis	9
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore	9
Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective	9
Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population	9
Clinical and economic burden of HPV-related cancers in the US veteran population	8
An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England	8
Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event	8
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore	8
Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis	8
Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective	8
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States	8
A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK	8
Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)	8
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States	8
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial	8
Hospitalization costs of adult community-acquired pneumonia in England	8
Economic burden of subsequent fracture in osteoporosis patients in South Korea	8
Pricing methods in outcome-based contracting: δ3: reference-based pricing	8
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing	8
Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database	8
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective	8
Fraudster’s and victims’ profiles and loss predictors’ hierarchy in the mental healthcare industry in the US	8
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants	7
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemoth	7
Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal	7
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany	7
Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of life	7
Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina	7
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective	7
Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patients	7
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data	7
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing	7
Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden	7
Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective	7
A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK	7
Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain	7
Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence	7
A review of the cost-effectiveness of genetic testing for germline variants in familial cancer	7
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus	7
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany	7
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors	7
Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada	7
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities	6
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain	6
Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain	6
Using electronic health record data to identify comparator populations for comparative effectiveness research	6
Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome	6
Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt	6
Payer budget impact of an artificial intelligence in vitro diagnostic to modify diabetic kidney disease progression	6
Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data	6
Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States	6
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database	6
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US	6
Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population	6
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	6
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016	6
Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales	6
Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France	6
Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes	6
Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention	6
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)	6
Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines	6
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evalu	6
Estimating the preferences and willingness-to-pay for colorectal cancer screening: an opportunity to incorporate the perspective of population at risk into policy development in Thailand	6
Healthcare utilization and cost burden of Huntington’s disease among Medicare beneficiaries in the United States	5
A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A	5
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States	5
Continuity and change in the drug supply chain: actors, actions, and aversions	5
Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients	5
Cost of hemophilia A in Turkey: an economic disease burden analysis	5

Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases	5
Informing a cost-effectiveness threshold for Saudi Arabia	5
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment	5
Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis	5
Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura	5
Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors	5
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer	5
Reply to the concerns raised by McKenna and Heaney about COSMIN	5
Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study	5
Use of real-world evidence in meta-analyses and cost-effectiveness models	5
Hospitalization charges for extremely preterm infants: a ten-year analysis in Shanghai, China	5
US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies	5
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization	5
Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison,	5
Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantati	5
Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease	5
The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi A	5
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis	5
Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care	5
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa	5
Budget impact analysis: can we afford the added value?	5
Healthcare resource utilization and costs for hip dislocation following primary total hip arthroplasty in the medicare population	5
Economic evaluation of home medication review by community pharmacists (HMR-CP) for patients with type 2 diabetes mellitus (T2DM)	5
Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis	5
Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints	5
Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis	5
Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis	5
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US	5
Utilities associated with stoma-related complications: peristomal skin complications and leakages	5
Continuing trends in U.S. brand-name and generic drug competition	5
Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs	5
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan	5